Viridian Therapeutics IncDE

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

VRDN$30.19+6.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share data)

Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive (Loss) Income · AccumulatedDeficit · TotalStockholders’Equity
Series A Convertible Preferred Stock · Series B Convertible Preferred Stock
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2021	260,437		$118,164		23,126			$15,669			23,924,004		$239			$412,101			$(157)			$(358,300)			$187,716
Issuance of common stock upon the conversion of convertible preferred stock	(72,056)		(32,694)		—			—			4,803,965		48			32,646			—			—			—
Issuance of Series B convertible preferred stock and common stock in the 2022 Public Offering, net of issuance costs of $2,992 and $18,146, respectively	—		—		28,084		41,008		11,352,640		114			248,528		—			—			289,650
Issuance of common stock, 2022 ATM, net of issuance costs of $926	—		—		—			—			964,357		10			24,150			—			—			24,160
Issuance of common stock upon exercises of warrants	—		—		—			—			56,666		1			934			—			—			935
Issuance of common stock for exercises of stock options	—		—		—			—			191,291		2			2,760			—			—			2,762
Issuance of common stock for cash under employee stock purchase plan	—		—		—			—			13,024		—			183			—			—			183
Share-based compensation expense	—		—		—			—			—		—			19,765			—			—			19,765
Change in unrealized loss on investments	—		—		—			—			—		—			—			(233)			—			(233)
Net loss	—		—		—			—			—		—			—			—			(129,874)			(129,874)
Balance as of December 31, 2022	188,381	$85,470		51,210			$56,677			41,305,947		$414			$741,067			$(390)			$(488,174)			$395,064
Issuance of common stock upon the conversion of convertible preferred stock	(15,946)		(7,235)		—			—			1,063,118		10			7,225			—			—			—
Issuance of common stock under license agreement	—	—		—			—			243,902			3			5,690			—			—			5,693
Issuance of Series B convertible preferred stock and common stock, 2023 Private Placement, net of issuance costs of $4,588 and $6,805, respectively	—	—		92,312		71,604			8,869,797			89			102,914			—			—			174,607
Issuance of common stock, September 2022 ATM, net of issuance costs of $493	—	—		—			—			684,298		7			14,761		—			—			14,768
Issuance of common stock upon exercises of warrants	—	—		—			—			114,219		1			1,880			—			—			1,881
Issuance of common stock for exercises of stock options	—	—		—			—			1,538,199		15			19,248			—			—			19,263
Issuance of common stock for cash under employee stock purchase plan	—	—		—			—			31,216		—			580			—			—			580
Vesting of restricted stock units	—	—		—			—			135,416		1			(1)			—			—			—
Share-based compensation expense	—	—		—			—			—		—			67,172			—			—			67,172
Change in unrealized gain on investments	—	—		—			—			—		—			—			728			—			728
Net loss	—	—		—			—			—		—			—			—			(237,734)			(237,734)
Balance as of December 31, 2023	172,435	$78,235		143,522			$128,281			53,986,112		$540			$960,536			$338			$(725,908)			$442,022
Issuance of common stock upon the conversion of convertible preferred stock	(37,571)		(17,047)		(18,362)			(24,085)			3,729,048		37			41,095			—			—			—

Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive (Loss) Income · AccumulatedDeficit · TotalStockholders’Equity
Series A Convertible Preferred Stock · Series B Convertible Preferred Stock
Shares · Amount · Shares · Amount · Shares · Amount
Issuance of common stock, January 2024 Public Offering, net of issuance costs of $9,304	—	—	—	—		7,142,858		71			140,625			—			—			140,696
Issuance of Series B convertible preferred stock and common stock, September 2024 Public Offering, net of issuance costs of $1,500 and $13,954, respectively	—	—	20,000	23,501		12,466,600			125			219,669			—			—			243,295
Issuance of common stock, September 2022 ATM, net of issuance costs of $2,156	—	—	—		—		3,058,751			31			67,724			—			—			67,755
Issuance of common stock for exercises of stock options	—	—	—	—		437,146		4			5,340			—			—			5,344
Issuance of common stock for cash under employee stock purchase plan	—	—	—	—		44,136		1			673			—			—			674
Vesting of restricted stock units	—	—	—		—		129,395			1			(1)			—			—			—
Share-based compensation expense	—	—	—	—		—		—			42,150			—			—			42,150
Change in unrealized gain/loss on investments	—	—	—	—		—		—			—			(348)			—			(348)
Net loss	—	—	—		—		—		—			—			—			(269,949)			(269,949)
Balance as of December 31, 2024	134,864	$61,188	145,160	$127,697		80,994,046		$810			$1,477,811			$(10)			$(995,857)			$671,639

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.